Box 2
Contains 32 Results:
Angiography with Iridium 191m: application for use permit, 1979
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Angiography with Iridium 191m: informed consent forms, reviews, 1982-1994
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Animal Protocol Forms: primates, rabbits, 1997-2000
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Cardiac Function Measurement with Iridium 191m: correspondence, 1982-1997
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Cardiac Function Measurement with Iridium 191m: study appendix, [1993]
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Cardiac Function Measurement with Iridium 191m: grant application, 1993-1994
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Cardiac Function Measurement with Iridium 191m: protocol amendments, 1993, 1995
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Cardiac Function Measurement with Iridium 191m: correspondence, grant proposals, reports, 1995-1998
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Cardiac Function Measurement with Iridium 191m: grant application, 1998
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Clinical Evaluation of Icon Gated SPECT: protocol application, 1993
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results